Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 38,600 shares, a decrease of 27.0% from the January 31st total of 52,900 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average daily volume of 74,500 shares, the short-interest ratio is currently 0.5 days.
Pulmatrix Stock Performance
Shares of NASDAQ PULM traded down $0.65 during mid-day trading on Tuesday, hitting $7.14. The stock had a trading volume of 55,830 shares, compared to its average volume of 38,787. The company has a 50 day moving average of $7.16 and a two-hundred day moving average of $4.66. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $10.40. The firm has a market cap of $26.08 million, a PE ratio of -2.70 and a beta of 1.61.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on Pulmatrix in a research report on Sunday, January 5th. They set a “hold” rating on the stock.
Hedge Funds Weigh In On Pulmatrix
A hedge fund recently raised its stake in Pulmatrix stock. Geode Capital Management LLC lifted its position in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) by 24.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,871 shares of the biotechnology company’s stock after acquiring an additional 7,290 shares during the period. Geode Capital Management LLC owned 1.01% of Pulmatrix worth $257,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 11.84% of the company’s stock.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Insider Trading – What You Need to Know
- GitLab: Get In While It’s Down—Big Rebound Ahead
- How to Profit From Value Investing
- Tesla Stock: Finding a Bottom May Take Time
- Short Selling – The Pros and Cons
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
